Role of quantitative human cytomegalovirus PCR in predicting antiviral treatment response among high-risk hematopoietic stem-cell transplant recipients [3]

Bone Marrow Transplantation

Volumn 33, Issue 4, 2004, Pages 463-464

  Safdar, A ^a,b   Bruorton, M ^a   Henslee Downey, J P ^a   van Rhee, F ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYTOMEGALOVIRUS ANTIGEN PP65; DACLIZUMAB; FOSCARNET; GANCICLOVIR; THYMOCYTE ANTIBODY; VIRUS DNA;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNITY; IMMUNOASSAY; LETTER; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECIPIENT; TREATMENT OUTCOME; UNITED STATES; VIRUS DETECTION; VIRUS REACTIVATION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; VIRAL LOAD; VIRUS ACTIVATION;

EID: 1542299727     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704375     Document Type: Letter

References (7)

1. Boiron JM, Lerner D, Pigneux A et al. Allogeneic transplantation for patients with advanced acute leukemia: a single center retrospective study of 92 patients. Leukemia Lymphoma 2001; 41: 285-296.
2. Avery RK, Adal KA, Longworth DL, Bolwell BJ. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 2000; 26: 763-767.
3. Qamruddin AQ, Oppenheim BA, Guiver M et al. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection. Bone Marrow Transplant 2001; 27: 301-306.
4. Guiver M, Fox AJ, Mutton K et al. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients. Transplantation 2001; 71: 1609-1615.
5. Henslee-Downey JP, Abhyankar SH, Parrish RS et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89: 3864-3872.
6. Nichols WG, Corey L, Gooley T et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcome. Blood 2001; 97: 867-874.
7. Emery VC, Sabin CA, Cope AV et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-2036.